ReviewBreast cancer research : BCR2000
Transforming growth factor-beta and breast cancer: Transforming growth factor-beta/SMAD signaling defects and cancer.
Review in Breast cancer research : BCR, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 1 synthesis or guideline pooled it.
- TRP Channels Interactome as a Novel Therapeutic Target in Breast Cancer.Frontiers in oncology · 2021Pooled it
- Jaboticaba peel extract limits castration-resistant prostate cancer aggressiveness by counteracting EMT through steroid hormone and TGF-β signaling modulation.Journal of molecular histology · 2026Article
- Article
- Mammalian Species-Specific Resistance to Mammary Cancer.Journal of mammary gland biology and neoplasia · 2025Review
- Immunotherapeutic Strategies Targeting Breast Cancer Stem Cells.Current oncology (Toronto, Ont.) · 2024Review
- The immune regulation and therapeutic potential of the SMAD gene family in breast cancer.Scientific reports · 2024Article
- Dual effect of vitamin DBMC cancer · 2024Article
- A novel GPI-anchored dominant-negative TGF-β receptor II renders T cells unresponsive to TGF-β signaling.Molecular therapy oncolytics · 2023Article
- IGF2BP2-modified UBE2D1 interacts with Smad2/3 to promote the progression of breast cancer.American journal of cancer research · 2023Article
- Article
- Physical Activity as the Best Supportive Care in Cancer: The Clinician's and the Researcher's Perspectives.Cancers · 2022Review
- In silico pathway analysis based on chromosomal instability in breast cancer patients.BMC medical genomics · 2020Article
- Expression pattern of p-Smad2/Smad4 as a predictor of survival in invasive breast ductal carcinoma.Oncology letters · 2020Article
- Adaptive Huber Regression.Journal of the American Statistical Association · 2020Article
- BMP-4 enhances epithelial mesenchymal transition and cancer stem cell properties of breast cancer cells via Notch signaling.Scientific reports · 2019Article
- Opposing roles and potential antagonistic mechanism between TGF-β and BMP pathways: Implications for cancer progression.EBioMedicine · 2019Review
- Soft Set Theory for Decision Making in Computational Biology under Incomplete Information.IEEE access : practical innovations, open solutions · 2019Article
- GIFT: Guided and Interpretable Factorization for Tensors with an application to large-scale multi-platform cancer analysis.Bioinformatics (Oxford, England) · 2018Article
- The Role of Platelet-Derived ADP and ATP in Promoting Pancreatic Cancer Cell Survival and Gemcitabine Resistance.Cancers · 2017Article
- STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.Cell cycle (Georgetown, Tex.) · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Transforming growth factor-beta (TGF-beta) is a tumor suppressor, the function of which is compromised in many types of human cancer, including breast cancer. The tumor suppressive effects of TGF-beta are caused by potent inhibition of cell proliferation due to cell cycle arrest in the G1 phase. Such antiproliferative responses are mediated by a signaling system that includes two types of cell surface receptors and intracellular signal transducers, the SMAD proteins. Different molecular mechanisms can lead to loss of antiproliferative TGF-beta responses in tumor cells, including mutations in components of the signaling system and inhibition of the SMAD signaling pathway by aberrant activities of various regulatory molecules. Some of these mechanisms will be discussed, with emphasis on their potential involvement in breast tumorigenesis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.